Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. - Wikidata - wikimedia - TriplyDB

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

http://www.wikidata.org/entity/Q43877873

about

Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis Peroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease.CCl4-induced hepatic injury in mice fed a Western diet is associated with blunted healing.Pioglitazone-induced myofibroblast cell death: implications for cutaneous scarring.Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation.Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis Difficulty with diagnosis of malignant pancreatic neoplasms coexisting with chronic pancreatitis Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-gamma.Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats Thiazolidinediones and hepatic fibrosis: don't wait too long.Stress- (and diet-) related regulation of hepatic nuclear receptors and its relevance for ABC-transporter functions.The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta)Effect of ligand of peroxisome proliferator-activated receptor gamma on the biological characters of hepatic stellate cells.The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR).Antifibrotic agents for liver disease.The possible role of peroxisome proliferator-activated receptor gamma in heart failure.Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator.Selective inhibition of activated stellate cells and protection from carbon tetrachloride-induced liver injury in rats by a new PPARgamma agonist KR62776.PPAR and liver injury in HIV-infected patients.Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.Animal models of alcoholic liver disease.Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.Molecular basis of organ fibrosis: potential therapeutic approaches.The stellate cell system (vitamin A-storing cell system).Novel Anti-fibrotic Therapies.Peroxisome proliferator-activated receptor gamma interacts with CIITA x RFX5 complex to repress type I collagen gene expression.Pre- and post-operative HBsAg levels may predict recurrence and survival after curative resection in patients with HBV-associated hepatocellular carcinoma.Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C.Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.Effects of PPARg agonist pioglitazone on rat hepatic fibrosis.Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells.Substitution for natural musk in Pien Tze Huang does not affect its hepatoprotective activities.Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage.Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice.PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.

P2860

Q28077583-3ACDA8CB-C53C-49AB-8C76-E39C0C632DBA Q33202380-F01BB54B-4C40-4C1E-9BC7-4E926632236B Q34192801-5E43C759-6885-4B98-A600-DC8B15734F29 Q34265266-1D831A33-62D9-456B-AB5A-80D758DEF9B7 Q34355908-DC294E83-2AF9-46E3-8EE0-00B3857BC459 Q35064467-D5460252-A804-47EA-A6E6-45E1FECB45EC Q35064548-B37AC914-F2F8-44CC-AD83-1111F6DAEDB6 Q35083721-3761C0CB-E247-463E-BEC5-052161E0D782 Q35115765-820161B5-8D9B-45F5-8A3F-A45698C9DF70 Q35170133-E20E7F1D-CC6B-4827-B150-CB6FA93F0752 Q35760670-13C01B9F-1CB6-4826-9653-C634C855DC53 Q35760700-5DE3CCDF-09D6-4621-B8E1-8F5FA722E540 Q35828054-14BB742A-AB2A-4DC4-A30C-573A76CF2E54 Q35842779-226E6F0F-5F0D-4582-BE32-82117EB83C89 Q36190403-9CC9EDD5-ED72-4275-9F56-94E4351B1514 Q36328530-F193B231-D94E-45E7-BD6E-B823191E1F47 Q36376477-81683434-74C1-4B7F-8004-6A244E1FA8E7 Q37277818-E1619B7E-2AFD-497C-8638-A2FD62DBF3EC Q37326935-395DE22E-322B-4FA5-AF71-BDB8849B3827 Q37329375-3685B0FE-312E-4484-864F-59133F252801 Q37458203-AD221DD9-FC63-4C15-B7F0-4A2EF32F7DFB Q37613264-10291C18-2BF7-46EF-BC58-AEA28A656C78 Q37869763-7B8F579F-3830-4CD5-8ACE-5684C3F5FCA4 Q38018841-A358AEC3-B66D-4F59-B930-E9C39AAD1EAE Q38121751-D876E9D3-A3CB-4683-874E-E420845E2DF6 Q38744473-E6D6F73B-02EB-4468-829D-1C45AD7C8972 Q39377055-FBB02EEA-A4B6-4905-96BC-35AC30C0AA6B Q40111521-08CD0779-54C6-4F57-92D3-D760B7CC672E Q40154210-1BC69CBD-2550-41CB-A974-6D8F1824E72B Q40211269-76D03A20-CB34-407D-A4D0-547B72C75949 Q41815307-B1B9C2A4-C97C-46CE-9136-F1345B9130D4 Q41908629-37A85D62-E31E-4764-AD0F-2E16757A9361 Q41926996-F45705EC-806D-4ADD-9463-EB0A491AF6A2 Q42027743-E3E74635-989F-4A0D-8CCB-6A72613D3EC6 Q43262336-D5284405-E9CA-433C-A466-8098121102D5 Q43263326-CD4D4CEA-6DD2-438B-B2ED-3AA2785BA55C Q44803419-59A639A6-733C-450D-983A-B87362EB1C95 Q45823107-AC5FD520-29E9-40F1-8772-A73D265F9C8F Q46127536-F70127D0-4AC7-4726-BE4F-B8923F69A67A Q46830543-0993F5B1-BF45-4D7A-8D06-91302A9DDFF2

P2860

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

http://www.wikidata.org/entity/Q43877873

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

@en

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

@nl

type

label

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

@en

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

@nl

prefLabel

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

@en

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

@nl

P1433

Q43877873-54FC69F8-B681-4B4B-A946-2AE8D508191B

P1476

Q43877873-5DE98FBD-CA06-4DB0-8367-D66D4ED8EC03

P2093

Q43877873-1B73A9CC-07EA-4630-9E7D-9D7C9D6AE91E

Q43877873-453104FD-EDC4-4761-8A1A-1638BE968271

Q43877873-9CAAC73F-0D8A-4EC3-B5A0-2DE87DA708B9

Q43877873-9D8D9825-5AFC-433A-B5B3-1955CE3DBE76

Q43877873-ADC0425E-F00F-41A4-8AEE-A5BE3C16B1C9

Q43877873-C211FC38-4CDB-4D9D-9783-68DEA40C7D74

Q43877873-FD84E382-24A5-4B48-9668-A30D4126D9B5

P304

Q43877873-C9AFFCCE-66A1-4D5F-BC74-FAF81A019365

P31

Q43877873-3F6B25D2-CB8A-4A8C-B0AC-5C16FCD620B5

P356

Q43877873-0CA3FAFE-FE3E-4145-B689-5F4663DF908F

P407

Q43877873-9A6BA9C1-A2B4-4F19-B112-E4E343D161F9

P433

Q43877873-0182B216-A144-47DC-8F85-48DBEB34D66B

P478

Q43877873-0196DCD1-7A7C-4434-B321-198B6BF493A0

P50

Q43877873-AFF9251E-166D-4F49-A195-5F896A669B29

P577

Q43877873-76962086-2577-4108-9E8E-6D6676A6E2B5

P698

Q43877873-2CA50430-537B-486C-ADAA-24449DAE5B28

P356

P1433

Biochemical and Biophysical Research Communications

P1476

Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride

@en

P2093

Kenichi Ikejima

http://www.w3.org/2001/XMLSchema#string

Miyoko Hirose

http://www.w3.org/2001/XMLSchema#string

Mutsuko Yoshikawa

http://www.w3.org/2001/XMLSchema#string

Nobuhiro Sato

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Enomoto

http://www.w3.org/2001/XMLSchema#string

Tsuneo Kitamura

http://www.w3.org/2001/XMLSchema#string

Yoshiyuki Takei

http://www.w3.org/2001/XMLSchema#string

P304

55-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1006/BBRC.2002.6385

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

291

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11829461

http://www.w3.org/2001/XMLSchema#string